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self-reported arthritis and those without arthritis reporting chronic or
sporadic joint symptoms compared to those who have no arthritis and
no joint symptoms.
Methods: Data from the 2008 Canadian Community Health Survey
(15+; n =66,013) were used for analyses. Respondents were asked about
arthritis as a long-term chronic health condition diagnosed by a health
professional. Participants not-reporting arthritis were asked about joint
symptoms excluding back and neck over the past 12 months. Analyses
were conducted for the following mutually exclusive groups: arthritis,
chronic joint symptoms (symptoms present on most days in the past
month), sporadic joint symptoms (other joint symptoms in the past
12 months (SJS)), and no arthritis and no joint symptoms (NJS). Log-
Poisson regression was used to determine risk factors for each of these
groups. Similar regressions, adjusting for socio-demographic, lifestyle
factors, and comorbidities were used to estimate the risks of reporting
physical inactivity, health outcomes (poor/fair overall health, poor/fair
mental health, activity limitation), and ﬁve measures of healthcare
use.
Results: 16.0% of the population reported arthritis, 10.1% reported CJS
and 11.6% reported SJS. Individuals with arthritis were older than those
with CJS or SJS. Women reported arthritis and CJS more often while men
reported SJS. Other than age, the proﬁle of risk factors for arthritis and
CJS was similar, notably obesity and overweight. After adjusting for age,
sex, SES, lifestyle factors and comorbidities, prevalence ratios showed
similar risks for physical inactivity, health outcomes and health care use
for the arthritis and CJS group, and these were higher than those for SJS
group.
Conclusions: CJS was reported by one-in-ten of the adult population. The
similarities in risk factors, other than younger age, for CJS and arthritis
suggest that the CJS group represent people in early stages of arthritis
(based on population frequency most likely osteoarthritis) who have not
yet being diagnosed. The impact that CJS has on health outcomes and
increased healthcare use was similar to that of arthritis, suggesting that
arthritis education and management interventions are likely beneﬁcial
for this group with possible unrecognized OA.
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Purpose: (1) To measure the telomere length of chondrocytes and
peripheral blood leukocytes (PBLs) in OA patients and healthy controls,
and (2) To analyze the incidence of the mtDNA haplogroup J in both
the telomere length and the Nitric Oxide (NO) production, as indirect
approaches of oxidative stress.
Methods: The telomere length was analyzed by means of a validated
qPCR method. For the comparison of the telomere length between
OA patients and healthy controls, the DNA was obtained from both
uncultured chondrocytes and blood of the same individual in a cohort
of 39 OA patients and 20 healthy controls from Hospital Universitario
A Corun˜a. A second larger cohort of 166 healthy controls and 79 OA
patients was used to compare the telomere length of PBLs between
haplogroup J (n = 155) and non-J carriers (n = 90), as well as between
OA patients and healthy controls. The NO production was assessed in
7 carriers of the haplogroup J and 21 non-J carriers by means of the
Griess reagent in the supernatants of cultured chondrocytes. Inducible
nitric oxide synthase (iNOS) mRNA from these samples was analyzed
by qPCR. Appropriated statistical approaches were carried out using
SPSS v1.17.
Results: The telomere length in chondrocytes was assessed as the
ratio “telomere length of chondrocytes: telomere length of PBLs of the same
individual”, and was signiﬁcantly shorter in OA patients than in healthy
controls (1.72±0.41 vs 2.12±0.64; mean±sd; p = 0.028). No statistical
differences were detected between OA patients and healthy controls
when analyzed the telomere length of PBLs in the larger cohort set;
however, carriers of the haplogroup J showed a signiﬁcantly longer
telomere length of PBLs than non-J carriers, regardless of age, gender
and diagnosis (p = 0.025). The NO production for chondrocytes carrying
this haplogroup was also signiﬁcantly lower (p = 0.05), and a strong
positive correlation between NO production and iNOS expression was
also observed (correlation coefﬁcient = 0.791, p < 0.001).
Conclusions: The decreased telomere length in chondrocytes from OA
affected joints may imply a local advanced senescence that could
contribute to the pathogenesis or progression of OA. The relation of
the mtDNA haplogroup J with both lower NO production and longer
telomere length of PBLs indicates a lower oxidative stress in carriers of
the mtDNA haplogroup J, which could explain the protective effect of
this haplogroup in the OA disease.
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Osteoarthritis (OA) is a complex disease of the joint, associated
with cartilage degradation by matrix proteases (aggrecanases and
collagenases). Nitric oxide (NO), the product of inducible nitric oxide
synthase (iNOS), not only suppresses the synthesis of cartilage matrix,
but also increases expression of proteases in OA; however, normal
chondrocytes do not produce NO. Although iNOS is readily inducible
in almost all rodent cell types in culture, in contrast, normal human
cells are recalcitrant to induction with cytokines due to epigenetic
silencing by DNA methylation. Unlike the murine iNOS promoter, the
ﬁrst 1.0 kb of the human iNOS gene 5′ ﬂanking region is not sufﬁcient for
iNOS induction. Instead, inducible NF-kB elements upstream −4.7 kb are
required for cytokine activation of the promoter. However, it is not known
whether the activation of iNOS in OA chondrocytes can be attributed to
epigenetic “unsilencing” with implications for therapeutic intervention
in OA.
Objective: To examine and correlate mRNA expression of iNOS with
the DNA methylation status of speciﬁc CpG sites in the iNOS promoter
and NF-kB enhancer elements regions, and to examine if the increased
expression of iNOS in OA chondrocytes is attributable to loss of DNA
methylation.
Methods: Control chondrocytes were obtained from fracture neck of
femur (#NOF) patients; these patients typically suffer from osteoporosis,
which does not affect the cartilage. #NOF patients are widely used as
a suitable non-OA control. OA chondrocytes were isolated from the
femoral heads of patients undergoing hip replacement surgery due
to OA. Genomic DNA and total RNA were extracted simultaneously.
Expression of iNOS was quantiﬁed by qRT-PCR and the DNA methylation
status of the iNOS promoter and enhancer regions was determined
by bisulﬁte modiﬁcation, followed either by cloning and sequencing
or pyrosequencer analysis to quantify percentage methylation. CpG
methylation on activities of both iNOS enhancer and promoter was
determined using reporter assay with CpG-free luciferase vector and
a CpG methyltransferase (M.SssI). On the other hand, co-transfections
with NF-kB subunits (p50, p65 and p50/p65) were carried out to analyse
the effect of this transcription factor on iNOS activity.
Results: OA samples showed a 13-fold increase in iNOS expression
compared to #NOF samples (n = 14, P< 0.05). The iNOS promoter has
only 7 CpG sites in over 1000bp, 6 of which were highly methylated
in both controls and OA and the CpG site at −289 was un-methylated
in both groups; the sites in the coding region (+13, +33 and +38), were
largely unmethylated in #NOF and OA patients. Three NF-kB enhancer
elements regions were analyzed by pyrosequencing, the enhancer regions
at −5.2 kb and −5.4 kb were found to be totally unmethylated in all
samples (<10%); however, the enhancer region at −5.8 was signiﬁcantly
de-methylated in OA samples (n = 12, P < 0.05) compared with #NOF
samples, with an approximate 10% loss of methylation. Transcriptional
activation of iNOS was possible after co-transfection of the −5.8 kb
enhancer element with p65 (45-fold increase, n = 5, P< 0.05) or p50/p65
NF-kB subunits (15-fold increase, n = 5, P< 0.05). Critically, methylation
treatment of the enhancer element was associated with a 25-fold
decrease in iNOS activity in reporter assay.
